PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
The Urban Collective is an app that allows tenants find properties that match their lifestyles. The app allows the user to share and rate properties. They intend on using the investment to add more functionality to the app.
days to go:
Expired
investment:
£283,428
Kiddyum have won multiple awards for their nutritious and delicious frozen meals for young children. They are currently stocked in over 320 sainsbury's nationwide and on Ocado.com. All ready meals are made from natural ingredients with no added sugar, preservatives, GM ingredients or artificial colours or flavours.
days to go:
Expired
investment:
£61,310
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
Landbay is a Buy-to Mortgage (BTM) lending platform that provides investors access to a flow of whole-loan high-quality BTL mortgages that can be securitised or held on a balance sheet. Landbay asserts that it does not deploy any of its own balance sheet nor take any credit risk. The company has completed over £600 million of mortgages to date. It argues that it has the mortgage funding, technology and capacity to grow significantly in the £250 billion mortgage market. The company was rated 'Excellent' on consumer review website Trustpilot. It will use 50% of the investment towards technology upgrade, 25% towards marketing and brand development, and 25% towards general marketing expenses.
days to go:
Expired
investment:
£5,129,548
TOAD is Oxford's first distillery, crafting gin, rye whiskey and vodka in bespoke stills using locally sourced populations of ancient heritage grain. Since launching in July 2017 they have achieved over £134k of revenue.
days to go:
Expired
investment:
£868,100
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.
days to go:
Expired
investment:
£1,835,892
Mr Lee's Noodles are an award winning, healthy, tasty and convenient noodles in a cup. They are low in salt, with no sat fats and are gluten free. They also have created an interactive noodle kiosk which delivers a hot noodle meal 24/7 and are looking to partner with catering and retail giants.
days to go:
Expired
investment:
£843,560
